Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01365130 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
A Phase 2 study, sponsored by howard safran.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01365130 is a Phase 2 study that was terminated before completion, run by howard safran. The registered enrollment target is 15 participants.
The verdict
NCT01365130, a Phase 2 study, was terminated before completion, sponsored by howard safran.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of Cabazitaxel, as well as safety and side effects for patients with advanced gastroesophageal cancer
Interventions
- DRUG jevtana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01365130
The ClinicalTrials.gov registry entry for NCT01365130 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is howard safran, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which jevtana is the first listed.
NCT01365130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01365130 about?
NCT01365130 is a clinical study titled "Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen". The purpose of this study is to evaluate the effectiveness of Cabazitaxel, as well as safety and side effects for patients with advanced gastroesophageal cancer
What is the current status of trial NCT01365130?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2011-06. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01365130?
The interventions under investigation include: jevtana (DRUG).
Who is sponsoring clinical trial NCT01365130?
This trial is sponsored by howard safran, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.